Alzheimer disease biomarkers as outcome measures for clinical trials in MCI

Anna Caroli, Annapaola Prestia, Sara Wade, Kewei Chen, Napatkamon Ayutyanont, Susan M. Landau, Cindee M. Madison, Cathleen Haense, Karl Herholz, Eric M. Reiman, William J. Jagust, Giovanni B. Frisoni

Research output: Contribution to journalArticlepeer-review


Background: The aim of this study was to compare the performance and power of the best-established diagnostic biological markers as outcome measures for clinical trials in patients with mild cognitive impairment (MCI). Methods: Magnetic resonance imaging, F-18 fluorodeoxyglucose positron emission tomography markers, and Alzheimer's Disease Assessment Scale-cognitive subscale were compared in terms of effect size and statistical power over different follow-up periods in 2 MCI groups, selected from Alzheimer's Disease Neuroimaging Initiative data set based on cerebrospinal fluid (abnormal cerebrospinal fluid Aβ1-42 concentration-ABETA+) or magnetic resonance imaging evidence of Alzheimer disease (positivity to hippocampal atrophy-HIPPO+). Biomarkers progression was modeled through mixed effect models. Scaled slope was chosen as measure of effect size. Biomarkers power was estimated using simulation algorithms. Results: Seventy-four ABETA+ and 51 HIPPO+ MCI patients were included in the study. Imaging biomarkers of neurodegeneration, especially MR measurements, showed highest performance. For all biomarkers and both MCI groups, power increased with increasing follow-up time, irrespective of biomarker assessment frequency. Conclusion: These findings provide information about biomarker enrichment and outcome measurements that could be employed to reduce MCI patient samples and treatment duration in future clinical trials.

Original languageEnglish
Pages (from-to)101-109
Number of pages9
JournalAlzheimer Disease and Associated Disorders
Issue number2
Publication statusPublished - Jun 9 2015


  • Alzheimer disease
  • biomarkers
  • biomarkers power
  • clinical trials
  • enrichment biomarkers
  • mild cognitive impairment
  • outcome measures

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Gerontology
  • Clinical Psychology


Dive into the research topics of 'Alzheimer disease biomarkers as outcome measures for clinical trials in MCI'. Together they form a unique fingerprint.

Cite this